<DOC>
	<DOCNO>NCT00081458</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability , pharmacokinetics ( PK ) teduglutide compare placebo subject parenteral nutrition ( PN ) -dependent short bowel syndrome ( SBS ) .</brief_summary>
	<brief_title>Safety Efficacy Study Teduglutide Subjects With Short Bowel Syndrome</brief_title>
	<detailed_description>Teduglutide analog glucagon-like peptide 2 ( GLP-2 ) , naturally occur hormone regulate growth , proliferation , maintenance cell line gastrointestinal tract . Teduglutide show animal study previous human clinical trial increase size number cell , thereby increase absorptive surface area intestine . The multicenter , double-blind , international Phase III trial randomly assign approximately 80 patient receive daily subcutaneous injection 0.05 milligram 0.10 milligram teduglutide per kilogram body weight , placebo . Dosing continue period six month . The primary endpoint study reduction use intravenous feeding , often require sustain life patient SBS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<criteria>Men woman , age 18 year age old time signing informed consent form ( ICF ) SBS result major intestinal resection result least 12 month intravenous feed Body weight must less 90 kg At baseline , subject must require PN treatment meet caloric electrolyte need due ongoing malabsorption least 3 time weekly stable PN regimen 4 week dose Body mass index ( BMI ) 18 27 kg/m2 Adequate hepatic renal function History cancer clinically significant lymphoproliferative disease few 5 year document diseasefree state History alcohol drug abuse ( within previous year ) Participation clinical study within 30 day prior sign ICF , concurrent participation clinical study Clinically significant laboratory abnormality time randomization Previous use teduglutide ( ALX0600 ) Prior use native GLP2 within 3 month screen visit Hospital admission within 1 month prior screen visit Pregnant lactate woman Any condition circumstance , investigator 's opinion would put subject undue risk , prevent completion study , interfere analysis study result . Presence exclude disease : Radiation enteritis , Scleroderma , Celiac disease , Refractory/Tropical sprue , Pseudoobstruction , Active inflammatory bowel disease ( IBD ) , Premalignant/malignant change colonoscopy biopsy polypectomy , Surgery schedule within time frame study , Human immunodeficiency virus ( HIV ) positive test , Immunological disorder , Possible allergy teduglutide constituent , Significant , active , uncontrolled , untreated systemic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Short Bowel Syndrome</keyword>
	<keyword>Parenteral Nutrition</keyword>
	<keyword>SBS</keyword>
</DOC>